Progress in Vascular Anesthesiology Donald M. Voltz, M.D. Assistant Professor of Anesthesiology Case Western Reserve University/University Hospitals of.

Slides:



Advertisements
Similar presentations
HEART TRANSPLANTATION
Advertisements

AGVISE Laboratories %Zone or Grid Samples – Northwood laboratory
The prevalence of use of beta- blockers in secondary prevention of myocardial infarctions in patients hospitalized 1 Institute of Epidemiology and biostatistics,
Β-blockers in Anesthesia Donald M. Voltz, M.D. Assistant Professor of Anesthesiology Case Western Reserve University/University Hospitals of Cleveland.
Prepared by: ACTION Registry-GWTG Results: January – December, 2008.
Perioperative Care: Preventing Complications
ALGEBRA Number Walls
OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.
2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Pediatric Recipients.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2008 J Heart Lung Transplant 2008;27:
Cardiovascular Risk and dyslipidemia
Multinational Comparisons of Health Systems Data, 2008 Support for this research was provided by The Commonwealth Fund. The views presented here are those.
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
CALENDAR.
Beta Blockers In Anesthesia. Introduction Introduction.
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels Frank M. Sacks, M.D., Marc A. Pfeffer,
Surgical Site Infections (SSIs): What the Direct Caregiver Should Know
Randall M. Zusman, MD Associate Professor of Medicine
MEND-CABG II ACC08 LBCT JHA, 1 John H. Alexander, MD, MS, FACC On behalf of the MEND-CABG II Investigators A Randomized, Double-blind, Placebo-controlled,
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
Copyright © 2012, Elsevier Inc. All rights Reserved. 1 Chapter 7 Modeling Structure with Blocks.
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Perioperative Issues Dr John Oyston Dept of Medicine Rounds April 15 th 2008.
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
CV Health: Three Ways to ‘kNOw’
Model and Relationships 6 M 1 M M M M M M M M M M M M M M M M
25 seconds left…...
Surgical Risk Dr Chris Snowden MD FRCA Consultant Anaesthetist
Week 1.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.
Staying Ahead of Cardiac Ischemia Glynne Stanley MB.ChB., FRCA Boston University School of Medicine 2 nd Annual Ellison Pierce Symposium Positioning Your.
1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.
Ryan Hampton January  Risks and benefits of surgery  Timing of surgery  Type of Surgery  Goal is to uncover undiagnosed problems or treat prior.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
What is Cardiology Clearance? Sheilah Bernard, MD, FACC Director, Cardiac Amb Services Sheilah Bernard, MD, FACC Director, Cardiac Amb Services 9:30-10:00am.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
Beta Blockade and the Heart John Hakim, M.D Cardiology Fellow West Virginia University Division of Cardiology.
Updated Peri-operative Guidelines AND POISE Trial
Journal Club Lei Zhang PGY 3 7/16/09. Case 55 y.o. F, PMH HTN, DM, TIA, and diverticulosis Had multitple diverticulitis, lower GIB in the past Scheduled.
Pre-op and Post-op Beta Blockers Alla Kotlyanskaya, Pharm.D. Clinical Pharmacist – Critical Care Woodhull Medical Center, Brooklyn, New York Adjunct Professor.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Department of OUTCOMES RESEARCH
Cardioprotective Agents in the Total Joint Arthroplasty Patient: Are We Doing Enough? Eric Schwenk MD*, Kishor Gandhi MD MPH*, Javad Parvizi MD^, Eugene.
Systemic Hypertension. Systemic blood pressure measures 140/90 mm Hg or higher on at least two occasions a minimum of 1 to 2 weeks apart.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
GRADE for reducing adverse outcomes actions to reduce adverse outcomes should be based on confidence in estimates of effectactions to reduce adverse outcomes.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Daniel I. Sessler Department of O UTCOMES R ESEARCH Cleveland Clinic on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
4S: Scandinavian Simvastatin Survival Study
Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
HOPE: Heart Outcomes Prevention Evaluation study
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
Making Surgery Safer: Preventing Post Operative Myocardial Infarctions
Western Norway B-vitamin Intervention Trial
The Hypertension in the Very Elderly Trial (HYVET)
Dr. PJ Devereaux on behalf of POISE Investigators
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Silent myocardial ischemia in patients undergoing peripheral vascular surgery: Incidence and association with perioperative cardiac morbidity and mortality 
Dr. PJ Devereaux on behalf of POISE Investigators
Clonidine in Patients Having Noncardiac Surgery
The role of a defined protocol for cardiac risk assessment in decreasing perioperative myocardial infarction in vascular surgery  T.J. Bunt, MD  Journal.
Presentation transcript:

Progress in Vascular Anesthesiology Donald M. Voltz, M.D. Assistant Professor of Anesthesiology Case Western Reserve University/University Hospitals of Cleveland

Overview Beta-blockers Fluid Therapy Regional Anesthesia

Beta-blockers in Vascular Patients Are We Using Too Few?

Вeta-Blockers Cardioprotection Hemodynamic Control Anesthetic Modification

B-blockers and Cardioprotection Well studied in vascular patient population Evolving evidence supports there use as a standard of care in at risk patients Likely to find increasing role in the future

B-blockers Evidence for Use

Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac Surgery Dennis T. Mangano, Ph.D., M.D., Elizabeth L. Layug, M.D., Arthur Wallace, Ph.D., M.D., Ida Tateo, M.S., for The Multicenter Study of Perioperative Ischemia Research Group Next Next Volume 335: December 5, 1996 Number 23

Mangano, et al Randomized trial of esmolol vs. saline (n=99, n=101) Patient followed for 2 years Mortality decreased in esmolol group 0% vs 8% at 6 months 0% vs 8% at 6 months 3% vs 14% at 1 year 3% vs 14% at 1 year 10% vs 21% at 2 years 10% vs 21% at 2 years

Wallace, et al pts randomized to atenolol or saline EKG, Holter monitor, and CPK w/ MB were followed 24 hr prior and 7 days after surgery Atenolol 0,5, or 10 mg or placebo prior to induction and every 12 hours until po than qd for 1 week

Wallace, et al Decreased perioperative myocardial ischemia 17/99 esmolol vs 34/101 placebo (days 0-2) 17/99 esmolol vs 34/101 placebo (days 0-2) 24/99 esmolol vs 39/101 placebo (days 0-7) 24/99 esmolol vs 39/101 placebo (days 0-7)

Polderman, et al pts with one or more cardiac risk factors; 173 positive dobutamine stress tests Bisoprolol in 59; Placebo in 53 Nonfatal MI 0% bisoprolol 0% bisoprolol 17% placebo group 17% placebo group Cardiac Death 3.4% bisoprolol group 3.4% bisoprolol group 17% placebo group 17% placebo group

What Patients are at Risk

B-blockers & At Risk Patients Presence of CAD History of Myocardial Infarction History of Myocardial Infarction Typical Angina or Atypical Angina with + Stress Test Typical Angina or Atypical Angina with + Stress Test At Risk for CAD (2 or more of the following) Age >65 years Age >65 years Hypertension Hypertension Active Smoker Active Smoker Serum Cholesterol > 240 mg/dl Serum Cholesterol > 240 mg/dl Diabetes Mellitus Diabetes Mellitus

B-blockers and Cardioprotection How well are we doing with at risk patients? Not Very Well! Not Very Well!

Prophylactic beta-blockade to prevent myocardial infarction perioperatively in high-risk patients who undergoing general surgical procedures. Taylor RC, Pagliarello G. Can J Surg Jun;46(3): pts for laparotomy 143 pts at risk for CAD 60.8% did not receive B-blockers pre-op 33% pts had B-blockers discontinued

The Effect of Heart Rate Control on Myocardial Ischemia Among High-Risk Patients After Vascular Surgery Khether E. Raby, MD, FACC *, Sorin J. Brull, MD, Farris Timimi, MD, Shamsuddin Akhtar, MD, Stanley Rosenbaum, MD, Cameron Naimi, BS, and Anthony D. Whittemore, MD Anesth Analg Mar;88(3):477-82

The Effect of Heart Rate Control on Myocardial Ischemia Among High-Risk Patients After Vascular Surgery Vascular Pts at High Risk for CAD underwent 24 hrs Holter Monitoring 26 of 150 pts had significant ischemia as measured by ST-depression – PreOp Randomized to Esmolol gtt (n=15) or Placebo (n=11) Titrated to HR 20% below ischemic threshold Titrated to HR 20% below ischemic threshold Holter Monitoring for 48 hrs PostOp

The Effect of Heart Rate Control on Myocardial Ischemia Among High-Risk Patients After Vascular Surgery Ischemia Present PostOp 73% in Placebo Group (8 of 11) 73% in Placebo Group (8 of 11) 33% in Esmolol Group (5 of 15) 33% in Esmolol Group (5 of 15) Number of Hours HR < Ischemic Threshold 9 of 15 pts in Esmolol group <20% and all without ischemia 9 of 15 pts in Esmolol group <20% and all without ischemia 4 of 11 pts in Placebo group <20%. 3 of 4 without ischemia 4 of 11 pts in Placebo group <20%. 3 of 4 without ischemia

B-blockers - Types EsmololMetoprololLabetelolAtenolol

Esmolol Ultra-short acting Quick onset (peak effect by 5 min) Loading dose 0.5 mg/kg Beta 1 selective IV route only Expensive

Metoprolol Can be given IV or PO Long acting (q6h dosing) Beta 1 selective Large doses may decrease the selectivity

Labetelol Can be given PO and IV Selective alpha 1 and nonselective beta 1,2 Alpha:Beta blocking properties 3:1 oral and 7:1 IV. (not clinically seen)

Atenolol Beta 1 selective Can be given IV or PO

B-blocker Adverse Reactions Bradycardia – is it symptomatic??? Bronchospasm in COPD/Asthma patients – no evidence to suggest problem in these patients with selective agents Heart Failure – use carefully in patients with low EF, however, has been shown to improve function with ACEI in end-stage CHF

Summary for At Risk Patients Preemptive Bradycardia Think about heart rate as separate from blood pressure Be aggressive with heart rate control Incorporate into preoperative and postoperative care. Involve Primary Care Physician Involve Primary Care Physician Involve Vascular Surgeon and Nursing Involve Vascular Surgeon and Nursing

Balanced Anesthesia and Beta-blockers

B-blockers and Anesthetic Reduction

Esmolol Promotes Electroencephalographic Burst Suppression During Propofol/Alfentanil Anesthesia Jay W. Johansen Anesth Analg 2001; 93:

Esmolol Promotes Electroencephalographic Burst Suppression During Propofol/Alfentanil Anesthesia N=20 patients Alfentanil Groups (50 or 150 ng/ml) Saline vs Esmolol infusion Monitored BIS output and Suppression Ratio

Esmolol Promotes Electroencephalographic Burst Suppression During Propofol/Alfentanil Anesthesia BIS Output Esmolol – 40% reduction (3722) Esmolol – 40% reduction (3722) Saline – no change Saline – no change Suppression Ratio Esmolol – 13.4 fold increase (5 67) Esmolol – 13.4 fold increase (5 67) Saline – no change Saline – no change

Efficacy of esmolol versus alfentanil as a supplement to propofol-nitrous oxide anesthesia Smith, J. Van Hemelrijck, and P. White Anesth Analg 2003;97:

Efficacy of esmolol versus alfentanil as a supplement to propofol- nitrous oxide anesthesia N=97 patients for arthroscopy Compared esmolol to alfentanil

Efficacy of esmolol versus alfentanil as a supplement to propofol-nitrous oxide anesthesia Esmolol decreased time to eye opening (7.2 vs 9.8 min) Esmolol reported more pain in PACU Esmolol required more opiods in PACU

Esmolol Potentiates Reduction in Minimal Alveolar Isoflurane Concentration Jay W. Johansen, et al. Anesth Analg 1998; 87:671-6

Esmolol Potentiates Reduction in Minimal Alveolar Isoflurane Concentration N=100; divided into 5 groups Isoflurane alone Isoflurane alone Isoflurane with large dose esmolol (250 mcg/kg/min) Isoflurane with large dose esmolol (250 mcg/kg/min) Isoflurane with Alfentanil Isoflurane with Alfentanil Isoflurane, Alfentanil, small dose esmolol (50 mcg/kg/min) Isoflurane, Alfentanil, small dose esmolol (50 mcg/kg/min) Isoflurane, Alfentanil, large dose esmolol (250 mcg/kg/min) Isoflurane, Alfentanil, large dose esmolol (250 mcg/kg/min)

Esmolol Potentiates Reduction in Minimal Alveolar Isoflurane Concentration MAC levels after steady state Isoflurane – 1.28% Isoflurane – 1.28% Iso + large dose Esmolol – 1.23% Iso + large dose Esmolol – 1.23% Iso + Alfentanil – 0.96%* Iso + Alfentanil – 0.96%* Iso + Alfentanil + small dose Esmolol – 0.96% Iso + Alfentanil + small dose Esmolol – 0.96% Iso + Alfentanil _ large dose Esmolol – 0.74%** Iso + Alfentanil _ large dose Esmolol – 0.74%**

Michael Zaugg, M.D.; Thomas Tagliente, M.D., Ph.D.; Eliana Lucchinetti, M.S.; Ellis Jacobs, Ph.D.; Marina Krol, Ph.D.; Carol Bodian, Dr.P.H.; David L. Reich, M.D.; Jeffrey H. Silverstein, M.D. ANESTHESIOLOGY 1999;91: Beneficial Effects from B-Adrenergic Blockade in Elderly Patients Undergoing Noncardiac Surgery

N=63 patients for noncardiac surgery Monitored – Neuropeptide Y, epinephrine, norepinephrine, cortisol, and ACTH Randomly assigned Group 1: no atenolol Group 1: no atenolol Group 2: Pre- and Post-operative atenolol Group 2: Pre- and Post-operative atenolol Group 3: Intraoperative Atenolol Group 3: Intraoperative Atenolol

Beneficial Effects from B-Adrenergic Blockade in Elderly Patients Undergoing Noncardiac Surgery Beta-blockade did not change neuroendocrine stress response Lower Narcotic Requirement Groups II and III – 27.7% less fentanyl Groups II and III – 27.7% less fentanyl Lower Anesthetic Requirements Group III – 37.5% less isoflurane (BIS same in all groups) Group III – 37.5% less isoflurane (BIS same in all groups) Lower PACU Morphine requirements Shorter PACU times

Beta-blockers and Bariatric Surgery Randomized Study of Morbidly Obese Patients Undergoing Gastric Bypass Metoprolol vs. Placebo Evaluate Intraoperative Volatile Requirements Intraoperative Volatile Requirements PACU Pain Requirement PACU Pain Requirement PCA Usage PCA Usage

Fluid Therapy for Vascular Patients Are We Using Way Too Much?

AAA Change in Anesthetic Care Retrospective study of AAA and anesthesia Patients for elective infra-renal AAA in 1991 and 2001 End-Points Time to extubation Time to extubation Intraoperative Fluid Administration Intraoperative Fluid Administration Time to return of Bowel Function Time to return of Bowel Function

AAA and Crystaloid Use

AAA Length of Stay

AAA and Bowel Function

Fluid Therapy in Vascular Patients Ensure adequate end-organ perfusion Treat hypotension of reperfusion with a combination of fluid and vasopressors Replace blood loss with blood, not crystaloid Question replacing insensible losses and NPO deficits by formulas.

Vascular Surgery and Regional Anesthesia

Benefits of Regional Anesthesia Cardiac Protection Preservation of Pulmonary Function Lower graft thrombosis Decrease postoperative hypercoagulable state Faster return of bowel function Superior postoperative analgesia Better immune function

Regional Anesthesia and Cardiac Protection Thoracic epidural a must, no benefit from lumbar catheter High level to block cardiac accelerator fibers Maintain an infusion or PCEA post- operatively for maximal benefits Low risk of bleeding if placed 1 hour prior to systemic heparinization

Regional Anesthesia and Cardiac Protection Still not clear Some studies show no difference The role of beta-blockers to control sympathetic response confounding No clear evidence regional is superior

Regional Anesthesia and Cardiac Protection Problems with regional anesthesia studies and cardiac protection Groups not normalized to heart rate? Groups not normalized to heart rate? Is the benefit only from cardiac accelerator fibers being blocked? Is the benefit only from cardiac accelerator fibers being blocked? Are there other benefits of beta-blockers not being used because of a high epidural level? Are there other benefits of beta-blockers not being used because of a high epidural level?

Is Reduced Cardiac Performance the Only Mechanism for Myocardial Infarction Size Reduction During beta-Adrenergic Blockade? Stangeland, L. Grong, K. Vik-Mo, H. Anderson, K. Levken, J. Cardiovasc Res 1986;20:

Stangeland, et al. Anaesthetized cats to elucidate if decreased heart rate was the mechanism for cardiac protection. Treated groups with either timolol or alinidine (clonidine derivative that decreases HR independently of Beta- receptors) Induced regional ischemia (LAD occlusion for 6 hours)

Stangeland, et al. Alinidine Group: Decreased Necrotic Area to 77% of control Decreased Necrotic Area to 77% of control Timolol Group: Decreased Necrotic Area to 65% of control Decreased Necrotic Area to 65% of control This data suggested another mechanism for beta-blocker cardioprotection other than heart rate control This data suggested another mechanism for beta-blocker cardioprotection other than heart rate control

Regional Anesthesia and Pulmonary Function FRC is decreased due to Diaphragmatic dysfunction of upper abdominal or thoracic incisions Diaphragmatic dysfunction of upper abdominal or thoracic incisions Decreased chest wall compliance Decreased chest wall compliance Incisional Pain Limitations Incisional Pain Limitations

Regional Anesthesia and Pulmonary Function Advantages for thoracic and upper abdominal surgery Unclear benefits in lower abdominal and peripheral surgery No Change in hospital LOS Time and Post-Op labor intensive Time to place Time to place Requires pain service to follow Requires pain service to follow

Regional Anesthesia and Pulmonary Function Currently are not using thoracic epidurals for AAA surgery Pain control in ICU and on Floor is adequate Surgeons and Anesthesiologists are in agreement to post-operative pain control

Regional Anesthesia and Pulmonary Function No increased incidence in pneumonia No delay in extubation for elective aortic or lower extremity surgery

Regional Anesthesia and Graft Thrombosis Improvement in lower extremity blood flow Decrease sympathetic activation and stimulation of coagulation system Systemic absorption of local anesthetics block thromboxane A2, platelet aggregation and reduce blood viscosity Large meta-analysis done in orthopedics looking at DVT. Abdominal surgery patients had a less significant effect Minimization of blood loss.

Regional Anesthesia and LOS No increase in LOS at our institution Unclear in literature if LOS is improved with regional anesthesia

Double-masked Randomized Trial Comparing Alternate Combinations of Intraoperative Anesthesia and Postoperative Analgesia in Abdominal Aortic Surgery Norris, E.J. et al. Anesthesiology 2001;95:

Norris et al. N=168 pts for elective aortic surgery Randomized to either epidural with light GA vs. GA alone Pts either with PCA or PCEA for 72h postoperatively

Norris et al. Postoperative outcomes were similar in groups MI, reoperation, renal failure, pneumonia MI, reoperation, renal failure, pneumonia LOS and direct medical costs LOS and direct medical costs VAS Pain Scores VAS Pain Scores Epidural groups with shorter Time to extubation (19 vs. 13 hours) Time to extubation (19 vs. 13 hours) ICU discharge (46 vs. 43 hours) ICU discharge (46 vs. 43 hours) Return of Bowel Function (111 vs. 102 hours) Return of Bowel Function (111 vs. 102 hours)

Regional Anesthesia and Bowel Function Thought to relate to narcotic use as well as sympathetic reflex arcs Thought is decreased sympathetic slowing while maintaining parasympathetic peristalis Problems with randomized studies are higher amounts of narcotics. Lower narcotic usage has impacted post- operative ileus in out institution

Regional Anesthesia and Vascular Surgery - Summary Not presently known if regional superior to beta-blockade for cardioprotection Regional may be beneficial in severely reduced pulmonary function patients Pain control is similar with IVPCA vs PCEA Unclear if additional factors are significant in vascular patients

THE END Vascular Anesthesia at University Hospitals of Cleveland